Stephanie D.S. HEIL

Dr. Stephanie D.S. HEIL

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2014 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Open access
PDF file
SHStephanie D.S. HEIL
Stephanie D.S. HEIL
CMCatherine Robbe Masselot
Catherine Robbe Masselot
AAAfifa Ait-Belgnaoui
Afifa Ait-Belgnaoui
AMAlessandro Mancuso
Alessandro Mancuso
MMMyriam Mercade-Loubière
Myriam Mercade-Loubière
MMMuriel Mercier-Bonin
Muriel Mercier-Bonin
Despite well-known intestinal epithelial barrier impairment and visceral hypersensitivity in irritable bowel syndrome (IBS) patients and IBS-like models, structural and physical changes in the mucus layer remain poorly understood. Using a water avoidance stress (WAS) model, we aimed at evaluating whether 1) WAS modified gut permeability, visceral sensitivity, mucin expression, biochemical structure of O-glycans, and related mucus physical properties, and 2) whether Lactobacillus farciminis treatment prevented these alterations. Wistar rats received orally L. farciminis or vehicle for 14 days; at day 10, they were submitted to either sham or 4-day WAS. Intestinal paracellular permeability and visceral sensitivity were measured in vivo. The number of goblet cells and Muc2 expression were evaluated by histology and immunohistochemistry, respectively. Mucosal adhesion of L. farciminis was determined ex situ. The mucin O-glycosylation profile was obtained by mass spectrometry. Surface imaging of intestinal mucus was performed at nanoscale by atomic force microscopy. WAS induced gut hyperpermeability and visceral hypersensitivity but did not modify either the number of intestinal goblet cells or Muc2 expression. In contrast, O-glycosylation of mucins was strongly affected, with the appearance of elongated polylactosaminic chain containing O-glycan structures, associated with flattening and loss of the mucus layer cohesive properties. L. farciminis bound to intestinal Muc2 and prevented WAS-induced functional alterations and changes in mucin O-glycosylation and mucus physical properties. WAS-induced functional changes were associated with mucus alterations resulting from a shift in O-glycosylation rather than from changes in mucin expression. L. farciminis treatment prevented these alterations, conferring epithelial and mucus barrier strengthening.

11 October 2017 in Brain Structure and Function
Verified
Journal Article
Closed access
PDF file
MRMarion Rincel
Marion Rincel
ALAmandine L. Lépinay
Amandine L. Lépinay
YJYoottana Janthakhin
Yoottana Janthakhin
GSGwenaëlle Soudain
Gwenaëlle Soudain
SYSophie Yvon
Sophie Yvon
MDMuriel Darnaudéry
Muriel Darnaudéry

24 February 2018 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
SHStephanie D.S. HEIL
Stephanie D.S. HEIL
ÅKÅsa V Keita
Åsa V Keita
SMSofie Mohlin
Sofie Mohlin
SPSven Påhlman
Sven Påhlman
VTVassilia Theodorou
Vassilia Theodorou
JSJohan D Söderholm
Johan D Söderholm
Peroxisome proliferator–activated receptor–gamma (PPARγ) exerts anti-inflammatory effects and is therefore a potential target in ulcerative colitis (UC). A novel PPARγ agonist (AS002) developed for local action was evaluated ex vivo in biopsies from UC patients and in vivo in mice with low-grade dextran sodium sulfate (DSS)– and trinitrobenzene sulfonic acid (TNBS)–induced colitis. Colonic biopsies from UC patients (n = 18) and healthy controls (n = 6) were incubated with AS002 or rosiglitazone (positive control) to measure mRNA expression of the PPARγ-responsive gene ADIPOPHILIN and protein levels of UC-related cytokines (enzyme-linked immunosorbent assay). AS002 absorption was determined in the colonic mucosa of UC patients. DSS-colitis mice received PPARγ agonists or vehicle daily by intrarectal administration starting 2 days before induction of colitis (preventive) or from days 3 to 8 (curative). Myeloperoxidase (MPO) and cytokine levels in colonic mucosa were determined. In addition, AS002 effects were studied in TNBS colitis. AS002 displayed an absorption pattern of a lipophilic drug totally metabolized in the mucosa. AS002 and rosiglitazone increased ADIPOPHILIN mRNA expression (3-fold) and decreased TNF-α, IL-1β, and IL-13 levels in human UC biopsies. In DSS, in both preventive and curative treatment and in TNBS colitis, AS002 protected against macroscopic and histological damage and lowered MPO and TNF-α, IL-1β, and IL-13 levels. AS002 triggers anti-inflammatory PPARγ activity in the human colonic mucosa of UC patients and prevents and reverses colitis in mice. Our data suggest that AS002 has potential for topical maintenance treatment of UC, which warrants further studies in vivo in patients.

14 September 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SHStephanie D.S. HEIL
Stephanie D.S. HEIL
CMCatherine Robbe Masselot
Catherine Robbe Masselot
ARArthur Raymond
Arthur Raymond
MMMyriam Mercade-Loubière
Myriam Mercade-Loubière
CSChristel Salvador-Cartier
Christel Salvador-Cartier
MMMuriel Mercier-Bonin
Muriel Mercier-Bonin
The present study aimed at detecting the exogenously applied probiotic Lactobacillus farciminis in rats, after exposure to IBS-like chronic stress, based on 4-day Water Avoidance Stress (WAS). The presence of L. farciminis in both ileal and colonic mucosal tissues was demonstrated by FISH and qPCR, with ileum as the preferential niche, as for the SFB population. A different spatial distribution of the probiotic was observed: in the ileum, bacteria were organized in micro-colonies more or less close to the epithelium whereas, in the colon, they were mainly visualized far away from the epithelium. When rats were submitted to WAS, the L. farciminis population substantially decreased in both intestinal regions, due to a stress-induced increase in colonic motility and defecation, rather than a modification of bacterial binding to the intestinal mucin Muc2.

9 February 2018 in Higher Education Policy
Verified
Journal Article
Closed access
PDF file
CSCarine Signoret
Carine Signoret
ENElaine Ng
Elaine Ng
SHStephanie D.S. HEIL
Stephanie D.S. HEIL
ATAyco Tack
Ayco Tack
Ulrikke VossUlrikke Voss
Ulrikke Voss
CBChanchal Balachandran
Chanchal Balachandran

6 September 2021 in Cells
Verified
Journal Article
Open access
PDF file
AMAndrea Molinas
Andrea Molinas
SHStephanie D.S. HEIL
Stephanie D.S. HEIL
SKStefan Koch
Stefan Koch
The CCNY gene, which encodes cyclin Y, has been implicated in the pathogenesis of inflammatory bowel disease (IBD). Cyclin Y promotes Wnt/β-catenin signaling and autophagy, which are critical for intestinal epithelial cell (IEC) homeostasis, and may thereby contribute to wound repair in colitis. However, whether cyclin Y has an essential function in IECs is unknown. We, therefore, investigated the epithelial injury response and mucosal regeneration in mice with conditional knock-out of Ccny in the intestinal epithelium. We observed that Ccny-deficient mice did not exhibit any differences in cell proliferation and disease activity compared to wild-type littermates in the dextran sulfate sodium (DSS) colitis model. Complementary in vitro experiments showed that loss of CCNY in model IECs did not affect Wnt signaling, cell proliferation, or autophagy. Additionally, we observed that expression of the cyclin-Y-associated cyclin-dependent kinase (CDK) 14 is exceedingly low specifically in IEC. Collectively, these results suggest that cyclin Y does not contribute to intestinal epithelial homeostasis, possibly due to low levels of specific CDKs in these cells. Thus, it is unlikely that CCNY mutations are causatively involved in IBD pathogenesis.